OBJECTIVES: To identify the dominant scheme of adjuvant breast cancer therapy (comparing the two chemotherapy regimens - 6FAÑ (6 cycles: 5-Fluorouracil + Doxorubicin +  Cyclophosphamide) vs 6DAC (6 cycles: Docetaxel + Doxorubicin +  Cyclophosphamide)). METHODS: Based on the Markov model, the cost of treatment for breast cancer was evaluated; an â òî æå âgåìÿ analysis of direct and indirect costs was conducted. Direct costs included cost of adjuvant chemotherapy (6FAC and 6DAC), medical services, adjuvant endocrine therapy, cardiac monitoring, current therapy cost and cost of treatment complications. Indirect costs included cost of patient’s disability, maintenance of orphans, GDP losses caused by mortality and disability and sick-pay. RESULTS: Based on a clinical study BCIRG 001 (Martin M, Mackey J, Pienkowski T) and as an outcome of Markov simulation it was determined that the use of 6DAC for adjuvant therapy in 10 year horizon of research allows to increase the disease-free survival by 6.09%, and overall survival by 5,88% comparing to 6FAC. Use of 6DAC instead of 6FAC allows to reduce the number of patients with local relapse, regional relapse and metastasis insignificantly as well. In the result of direct costs analysis it was determined that for 10-years horizon cost rate for the treatment of one patient with breast cancer will be $66,026 for 6DAC and $60,845 for 6FAC. Direct and indirect costs rate of the breast cancer treatment were $84,818 and $85,991 for the 6DAC and 6FAC schemes respectively. CONCLUSIONS: It was determined that the scheme of adjuvant therapy that includes Docetaxel besides of addition efficiency, allows to reduce the cost rate to $1173 in 10 years.